A5084829703- Antimicrobial Resistance in Staphylococcus
- Antibiotics Pharmacokinetics and Efficacy
- Bacterial Identification and Susceptibility Testing
- Antibiotic Resistance in Bacteria
- Infective Endocarditis Diagnosis and Management
- Streptococcal Infections and Treatments
- Pneumonia and Respiratory Infections
- Antibiotic Use and Resistance
- Bacterial biofilms and quorum sensing
- Antifungal resistance and susceptibility
- Bacteriophages and microbial interactions
- Mycobacterium research and diagnosis
- Antimicrobial Peptides and Activities
- Clostridium difficile and Clostridium perfringens research
- Biochemical and Structural Characterization
- Microbial infections and disease research
- Nosocomial Infections in ICU
- Pneumocystis jirovecii pneumonia detection and treatment
- Pharmaceutical studies and practices
- Orthopedic Infections and Treatments
- Cholinesterase and Neurodegenerative Diseases
- Cancer therapeutics and mechanisms
- Phenothiazines and Benzothiazines Synthesis and Activities
- Tuberculosis Research and Epidemiology
- Drug-Induced Adverse Reactions
Eugene Applebaum College of Pharmacy and Health Sciences
2016-2025
Wayne State University
2016-2025
Detroit Receiving Hospital
2016-2025
Detroit Medical Center
2015-2024
Harper University Hospital
2023
American College of Clinical Pharmacy
2020
University of North Carolina at Pembroke
2020
Indianapolis Zoo
2020
Michigan United
2020
American Heart Association
2015
Evidence-based guidelines for the management of patients with methicillin-resistant Staphylococcus aureus (MRSA) infections were prepared by an Expert Panel Infectious Diseases Society America (IDSA). The are intended use health care providers who adult and pediatric MRSA infections. discuss a variety clinical syndromes associated disease, including skin soft tissue (SSTI), bacteremia endocarditis, pneumonia, bone joint infections, central nervous system (CNS) Recommendations provided...
Evidence-based guidelines for the management of patients with methicillin-resistant Staphylococcus aureus (MRSA) infections were prepared by an Expert Panel Infectious Diseases Society America (IDSA). The are intended use health care providers who adult and pediatric MRSA infections. discuss a variety clinical syndromes associated disease, including skin soft tissue (SSTI), bacteremia endocarditis, pneumonia, bone joint infections, central nervous system (CNS) Recommendations provided...
Recent clinical data on vancomycin pharmacokinetics and pharmacodynamics suggest a reevaluation of current dosing monitoring recommendations. The previous 2009 consensus guidelines recommend trough as surrogate marker for the target area under curve over 24 hours to minimum inhibitory concentration (AUC/MIC). However, recent that is associated with higher nephrotoxicity. This document an executive summary new monitoring. It was developed by American Society Health-System Pharmacists,...
Practice guidelines for therapeutic monitoring of vancomycin treatment Staphylococcus aureus infection in adult patients were reviewed by an expert panel the Infectious Diseases Society America, American Health-System Pharmacists, and Pharmacists. A literature review existing evidence regarding dosing serum concentrations, addition to patient outcomes combined with opinion drug's pharmacokinetic, pharmacodynamic, safety record, resulted new recommendations targeting adjustment therapy.
The objective of this study was to determine the effect delayed therapy on morbidity and mortality associated with nosocomial Staphylococcus aureus bacteremia. included all episodes S. bacteremia that developed >2 days after hospital admission during 1999 2001. Classification regression tree analysis (CART) used select breakpoint between early treatment. During 25-month period, 167 patients met inclusion criteria. treatment derived using CART 44.75 hours. On multivariate analysis, found be...
(See the article by Patel et al, on pages 969–974.) Background. High rates of vancomycin failure in methicillin-resistant Staphylococcus aureus (MRSA) infections have been increasingly reported over time. The primary objective our study was to determine impact exposure and outcomes patients with MRSA bacteremia initially treated vancomycin. Methods. This a single-center retrospective analysis 320 documented from January 2005 through April 2010. Two methods susceptibility, Etest broth...
ABSTRACT The nephrotoxicity and ototoxicity associated with once-daily versus twice-daily administration of aminoglycosides was assessed in patients suspected or proven gram-negative bacterial infections a randomized, double-blind clinical trial. Patients who received therapy for ≥72 h were evaluated toxicity. also concomitant antibiotics as deemed necessary treatment their infection. Plasma aminoglycoside concentrations, prospective dosage adjustment, serial audiologic renal status...
Journal Article Nephrotoxicity of vancomycin, alone and with an aminoglycoside Get access Michael J. Rybak, Rybak aCollege Pharmacy Allied Health ProfessionsDetroit, Michigan 48201, USAdDepartment Services, Detroit Receiving Hospital University CenterDetroit, USA Corresponding author: Dr J Department Center, 4201 St Antoine Boulevard, Detroit, Search for other works by this author on: Oxford Academic PubMed Google Scholar Lisa M. Albrecht, Albrecht cCollege Pharmacy, Illinois at Chicago...
Abstract Recent clinical data on vancomycin pharmacokinetics and pharmacodynamics suggest a reevaluation of current dosing monitoring recommendations. The previous 2009 consensus guidelines recommend trough as surrogate marker for the target area under curve over 24 hours to minimum inhibitory concentration (AUC/MIC). However, recent that is associated with higher nephrotoxicity. This document an executive summary new monitoring. It was developed by American Society Health-System...
ABSTRACT Evidence suggests that maintenance of vancomycin trough concentrations at between 15 and 20 mg/liter, as currently recommended, is frequently unnecessary to achieve the daily area under concentration-time curve (AUC 24 ) target ≥400 mg · h/liter. Many patients with in this range have AUC values excess therapeutic threshold within exposure associated nephrotoxicity. On basis this, Detroit Medical Center switched from concentration-guided dosing AUC-guided minimize potentially...
Recent evidence suggests that among patients receiving vancomycin, receipt of concomitant piperacillin-tazobactam increases the risk nephrotoxicity. Well-controlled, adequately powered studies comparing rates acute kidney injury (AKI) vancomycin + (VPT) compared to similar cefepime (VC) are lacking. In this study we incidence AKI combination therapy with VPT a matched group VC.A retrospective, matched, cohort was performed. Patients were eligible if they received for ≥48 hours. excluded...
BackgroundPneumonia and bloodstream infections (BSI) due to extensively drug-resistant (XDR) Acinetobacter baumannii, XDR Pseudomonas aeruginosa, carbapenem-resistant Enterobacterales (CRE) are associated with high mortality rates, therapeutic options remain limited. This trial assessed whether combination therapy colistin meropenem was superior monotherapy for the treatment of these infections.MethodsThe OVERCOME (Colistin Monotherapy versus Combination Therapy) an international,...
The in vitro activity of daptomycin was compared with those vancomycin, linezolid, and quinupristin-dalfopristin against a variety (n = 203) gram-positive bacteria, including methicillin-resistant Staphylococcus aureus S. epidermidis (MRSA MRSE, respectively), vancomycin-resistant enterococci (VRE), vancomycin-intermediate (VISA). Overall, more active all organisms tested, except Enterococcus faecium VISA, which its similar to that quinupristin-dalfopristin. In time-kill studies MRSA, VRE,...
ABSTRACT We evaluated the impact of high (9.5 log 10 CFU/g) and moderate (5.5 inocula methicillin-susceptible -resistant S taphylococcus aureus (MSSA MRSA, respectively) on activities nafcillin, linezolid, vancomycin, daptomycin, alone in combination with gentamicin an vitro pharmacodynamic model simulated endocardial vegetations over 72 h. Human therapeutic dosing regimens for were simulated. At a inoculum, nafcillin only), daptomycin demonstrated equivalent significant ( P < 0.01)...
We conducted a prospective, open-label study to delineate relationship between exposure and outcomes in 36 patients treated with cefepime. Twenty had documented Gram-negative infections. Timed blood urine samples were obtained at steady state determine pharmacokinetic pharmacodynamic parameters. Microbiological success was significantly correlated the proportion of dosing interval that cefepime concentrations exceeded 4.3 × MIC. Our results support vitro data suggest bactericidal activity...
The prevalence of drug-resistant bacteria drives the quest for new antimicrobials, including those that are not expected to readily engender resistance. One option is mimic Nature's most ubiquitous means controlling bacterial growth, antimicrobial peptides, which have evolved over eons. In general, remain susceptible these peptides. Human peptides play a central role in innate immunity, and deficiencies been tied increased rates infection. However, clinical use hampered by issues cost...